Safety Specification

This part of an RMP provides a synopsis of a medicinal product’s safety. It should be a summary of:

  • The important identified risks
  • Important potential risks
  • Missing information

It should also address:

  • Populations potentially at risk (where the product is likely to be used in labelled and off-labelled use)
  • Safety questions which warrant further investigation during the post-authorization period


Take advantage of the knowledge and best practices gained from more than 20 years of research, innovation and development for the health and life sciences sectors.


The Life Sciences glossary with terminology, acronyms, for regulatory, quality, compliance, clinical trials, and pharmacovigilance software.

Found 370 Results
Page 1 of 2



Page 1 of 2